Oxybutynin Treatment for Overactive Bladder
Introduction to Oxybutynin Therapy
- The American Urological Association recommends oxybutynin as second-line pharmacotherapy for overactive bladder (OAB) after behavioral therapies, with dosing starting at 5 mg two to three times daily for immediate-release formulations or 5-10 mg once daily for extended-release formulations, due to its efficacy in reducing symptoms, 1, 2
- Beta-3 agonists are typically preferred before antimuscarinics due to lower dementia risk, as stated by the American Urological Association, 1, 2
Treatment Algorithm
- All patients with OAB must receive behavioral therapies first, including bladder training, fluid management, caffeine reduction, physical activity/exercise, and dietary modifications, as recommended by the American Urological Association, 3, 4
- Bladder training has the strongest evidence base among behavioral interventions and should be emphasized, according to the American Urological Association, 1, 5
- These therapies can be combined with pharmacotherapy if monotherapy fails, as suggested by the American Urological Association, 1, 2
Critical Safety Screening
- Narrow-angle glaucoma is an absolute contraindication for oxybutynin use, as stated by the American Urological Association, 1, 2, 5
- Impaired gastric emptying is an absolute contraindication for oxybutynin use, according to the American Urological Association, 1, 2, 5
- History of urinary retention is an absolute contraindication for oxybutynin use, as recommended by the American Urological Association, 1, 2, 5
- Patients taking solid oral potassium chloride are at increased risk of absorption, as noted by the American Urological Association, 6
Managing Treatment Response
- If inadequate response to oxybutynin, consider switching to alternative antimuscarinic with better tolerability, such as solifenacin or darifenacin, as suggested by the American Urological Association, 5
- Combination therapy by adding behavioral therapy to pharmacotherapy may be considered, according to the American Urological Association, 1, 2
- Refractory patients may require referral to a specialist for third-line treatments, including sacral neuromodulation, peripheral tibial nerve stimulation, or onabotulinumtoxinA injections, as recommended by the American Urological Association, 6, 5